Peer reviewed
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT)
Cardiovascular outcomes trial showing semaglutide reduced major adverse CV events in non-diabetic patients with obesity.
New England Journal of MedicinePublished 2023-12-14Accessed 2026-07-01
Registry record
Source metadata
- Publisher
- New England Journal of Medicine
- Source type
- Peer reviewed
- Registry ID
nejm-semaglutide-select-2023
Interpretation boundary
What this record can and cannot establish
Inclusion in the registry is not endorsement. The record supports only the claims that fit its design, population, date, and scope. Company, media, and community records can document that a claim was made without proving the claim itself.